About the Company
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RTRX News
KaloBios Plunges 50 Percent After CEO Martin Shkrelis Arrest
Prosecutors have charged Shkreli with illegally taking stock from Retrophin Inc., a biotechnology firm he started in 2011, and using it pay off debts from unrelated business dealings. (Bloomberg) — ...
Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease
Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan. Retrophin announced positive results ...
Retrophin Tanks After Neurological Treatment Fails Late-Stage Study
Shares of drugmaker Retrophin (RTRX) were sinking Thursday after the company announced that its drug candidate for a rare nuerological disorder failed a late-stage study. The San Diego-based ...
US sells Wu-Tang album to settle ‘Pharma Bro’ Shkreli’s court debt
Shkreli was the founder and managing member of hedge funds MSMB Capital Management and MSMB Healthcare Management, and the CEO of biopharmaceutical company Retrophin Inc. A jury found Shkreli guilty ...
Trial Kicks Off for Ex-Lawyer of Jailed ‘Pharma Bro’ Martin Shkreli
As an attorney with Katten Muchin Rosenman from 2012 to 2014, Evan Greebel served as lead outside counsel for Shkreli’s biopharmaceutical company, Retrophin. The 44-year-old faces counts of conspiracy ...
30 CEO Salaries That Show America's Execs Are Overpaid
Brands, Inc. which includes Taco Bell ... His net worth was around $70 million as the former CEO of former CEO of Retrophin and Turing Pharmaceuticals, but that was before he became a convicted ...
how did martin shkreli become rich?
Why do they call Martin shkreli Pharma Bro? Mr. Shrkeli played a major role in driving up the price of Daraprim, a toxoplasmosis drug, which the Swiss company owns the rights to, earning him the ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Netlist, Inc. (NLST)
Netlist, Inc. (PNK:NLST) Q1 2024 Earnings Call Transcript April 25, 2024 Netlist, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.05. NLST isn’t one of ...
Inc. 5000 Conference
She spoke at the 2023 Inc. 5000 Conference about the difference between marketing and advertising. At the Inc. 5000 Conference, Howroyd, the first Black woman to build and own a billion-dollar ...
Loading the latest forecasts...